All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Undisclosed
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: $1,060.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 12, 2021
Details:
Agreement and partnership with Boehringer Ingelheim provides additional validation of Enara Bio’s EDAPT™ platform and Dark Antigen™ discovery work and supports ongoing cell therapy based therapeutic approach.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Metalloenzyme-targeted medicines
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $300.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 08, 2021
Details:
Blacksmith and Lilly will collaborate on up to 5 human metalloenzyme targets, with Blacksmith advancing novel small molecule inhibitors from fragment to 'hit' stage after which Lilly has the right to continue research, development, and commercialization.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ALT-B4,Undisclosed
Therapeutic Area: Oncology Product Name: ALT-B4
Highest Development Status: Discovery Platform Product Type: Large molecule
Partner/Sponsor/Collaborator: Intas Pharmaceuticals
Deal Size: $109.0 million Upfront Cash: $6.0 million
Deal Type: Collaboration January 07, 2021
Details:
Under the terms of the agreement, Alteogen has granted worldwide rights, except for a few Asian countries, for Intas to develop two products in combination with ALT-B4.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Long-acting Therapeutic antibodies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Large molecule
Partner/Sponsor/Collaborator: Optimeos
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 07, 2021
Details:
The partnership will leverage Integral Molecular's industry-leading platform for antibody discovery and include novel targets in cancer and autoimmune diseases.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Oncolytic viral therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Large molecule
Partner/Sponsor/Collaborator: Epidarex Capital
Deal Size: $6.8 million Upfront Cash: Undisclosed
Deal Type: Series A Financing January 07, 2021
Details:
The financing will be used to progress the company’s Oncolytic viral therapies towards human clinical trials.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Allogeneic CAR T-cells
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Cellectis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 07, 2021
Details:
Through this license agreement, SIRION Biotech GmbH (“SIRION”) granted Cellectis non-exclusive right under its proprietary lentiviral transduction enhancer LentiBOOST™.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): RNA-Targeted Therapeutics
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Small molecule
Partner/Sponsor/Collaborator: Genentech
Deal Size: $1,025.0 million Upfront Cash: $25.0 million
Deal Type: Collaboration January 06, 2021
Details:
Ribometrix will apply its proprietary discovery platform to identify and optimize small molecule compounds that modulate RNA function by targeting three-dimensional (3D) RNA structures.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Bispecific antibodies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Large molecule
Partner/Sponsor/Collaborator: UNIV TX MD ANDERSON
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 06, 2021
Details:
Collaboration joins Xencor’s innovative XmAb® technology and protein engineering expertise to create bispecific antibodies with MD Anderson’s ORBIT platform, part of MD Anderson’s Therapeutics Discovery division.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Small molecule
Partner/Sponsor/Collaborator: FutuRx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 18, 2020
Details:
As part of the strategic partnership, Atomwise will work closely with the FutuRx management team, investors and incubated portfolio companies to apply its AI technology to early-stage drug discovery projects.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Human antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Large molecule
Partner/Sponsor/Collaborator: Xencor
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 07, 2020
Details:
Under the terms of the agreement, Xencor, Inc., gets rights to Biocytogen’s fully human antibody RenMab™/RenLite™ Mouse platform to enhance Xencor’s monoclonal antibody drug discovery research.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
